Carregant...
Should minimal residual disease negativity not be the end point of myeloma therapy?
Publisher's Note: This article has a companion Point by Anderson. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.
Guardat en:
| Publicat a: | Blood Adv |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5728450/ https://ncbi.nlm.nih.gov/pubmed/29296971 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017000109 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|